Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Current Liabilities: 2015-2025

Historic Total Current Liabilities for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $46.3 million.

  • Spyre Therapeutics' Total Current Liabilities fell 19.58% to $46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.3 million, marking a year-over-year decrease of 19.58%. This contributed to the annual value of $54.1 million for FY2024, which is 69.05% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Total Current Liabilities of $46.3 million as of Q3 2025, which was down 44.29% from $83.1 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Total Current Liabilities peaked at $232.2 million during Q2 2023, and registered a low of $12.6 million during Q1 2023.
  • Its 3-year average for Total Current Liabilities is $63.5 million, with a median of $46.3 million in 2025.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 1,364.09% in 2023, then tumbled by 90.47% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Total Current Liabilities (Quarterly) stood at $20.1 million in 2021, then decreased by 27.24% to $14.7 million in 2022, then skyrocketed by 118.19% to $32.0 million in 2023, then spiked by 69.05% to $54.1 million in 2024, then decreased by 19.58% to $46.3 million in 2025.
  • Its last three reported values are $46.3 million in Q3 2025, $83.1 million for Q2 2025, and $70.7 million during Q1 2025.